The Raindrop near vision inlay yielded significant improvements in near and intermediate visual acuity in patients with emmetropic presbyopia, according to a study. The prospective FDA investigational device exemption clinical trial included 373 eyes f…
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/f75x2s/global) has announced the addition of the “Global Age-related Macular Degeneration Partnering 2010 to 2016” report to their offering. The Global Age-Relate…
ThromboGenics has signed an exclusive licensing agreement with Galapagos to develop and commercialize integrin antagonists to treat diabetic eye disease, according to a press release. ThromboGenics will pay a 1 million upfront technology transfer payment to Galapagos, and Galapagos will receive development and commercial milestone payments and royalties based on any future net sales from products that originated from Galapagos’ library of integrin antagonists.
At OSN New York, John A. Hovanesian, MD, FACS, discusses how the use of follow-up care software in the ophthalmic practices can increase patient satisfaction.
At OSN New York, P. Dee Stephenson, MD, FACS, discusses how customized femtosecond laser fragmentation can further reduce phacoemulsification time over standard femtosecond laser fragmentation.
At OSN New York, Andrew A. Moshfeghi, MD, talks about the evolution of retinal imaging.